On June 24, 2025, Gain Therapeutics, Inc. increased its authorized shares of common stock from 50 million to 100 million, approved at their annual meeting where directors and the accounting firm Ernst & Young were also voted in. This increase enhances their capital structure and supports future growth initiatives.